Evoke Pharma Inc Revenue Growth Rates (EVOK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Evoke Pharma Inc   (NASDAQ: EVOK)
 

EVOK's Revenue Growth by Quarter and Year

Evoke Pharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVOK Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September 4.28
2nd Quarter June 3.75
1st Quarter March 3.08
FY 11.11

EVOKs Annual Revenue
Evoke Pharma Inc 's Revenue in the fiscal year 2024 $ 10.25 millions
Evoke Pharma Inc 's Revenue in the fiscal year 2023 $ 5.18 millions
Evoke Pharma Inc 's Revenue in the fiscal year 2022 $ 2.51 millions
Evoke Pharma Inc 's Revenue in the fiscal year 2021 $ 1.62 millions
Evoke Pharma Inc 's Revenue in the fiscal year 2020 $ 0.02 millions




EVOK Revenue third quarter 2025 Y/Y Growth Comment
Evoke Pharma Inc reported Revenue surge of 61.66% year on year in the third quarter 2025, to $ 4.28 millions, this is lower than Evoke Pharma Inc 's recent average Revenue surge of 147.96%.

Looking into third quarter 2025 results within Major Pharmaceutical Preparations industry 49 other companies have achieved higher Revenue growth. While Evoke Pharma Inc ' s Revenue jump of 61.66% ranks overall at the positon no. 295 in the third quarter 2025.


EVOK Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 97.02 % 110 % 122.22 %
3rd Quarter September 61.66 % 69.87 % 87.95 % -10.75 %
2nd Quarter June 47.06 % 125.66 % 145.65 % 91.67 %
1st Quarter March 77.01 % 114.81 % 92.86 % 366.67 %
FY   - 97.88 % 106.37 % -

Financial Statements
Evoke Pharma Inc 's third quarter 2025 Revenue $ 4.28 millions EVOK's Income Statement
Evoke Pharma Inc 's third quarter 2024 Revenue $ 2.65 millions Quarterly EVOK's Income Statement


EVOK Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 24.91 % 7.69 % -3.61 %
3rd Quarter September 14.24 % 3.92 % 38.05 % 80.43 %
2nd Quarter June 21.75 % 46.55 % 39.51 % 9.52 %
1st Quarter March -6.95 % 3.57 % 1.25 % 16.67 %
FY (Year on Year)   - 97.88 % 106.37 % -


Back to EVOK Growth rate Comparisons >> Back to EVOK Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #81
Overall #295

Revenue Y/Y Growth Statistics
High Average Low
1466.34 % 147.96 % -100 %
(Jun 30 2024)   (Mar 31 2023)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #50
Healthcare Sector #81
Overall #295
Revenue Y/Y Growth Statistics
High Average Low
1466.34 % 147.96 % -100 %
(Jun 30 2024)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Evoke Pharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
293.2 % 38.2 % -100 %
(Sep 30 2021)  


EVOK's III. Quarter Q/Q Revenue Comment
Evoke Pharma Inc achieved in the III. Quarter 2025 below company average Revenue rise of 14.24% quarter on quarter, to $ 4.28 millions.

III. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.92% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Evoke Pharma Inc 's Revenue growth quarter on quarter, overall rank is 574.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #119
Overall #574
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #119
Overall #574
Revenue Q/Q Growth Statistics
High Average Low
293.2 % 38.2 % -100 %
(Sep 30 2021)  


EVOK's III. Quarter Q/Q Revenue Comment
Evoke Pharma Inc achieved in the III. Quarter 2025 below company average Revenue rise of 14.24% quarter on quarter, to $ 4.28 millions.

III. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.92% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Evoke Pharma Inc 's Revenue growth quarter on quarter, overall rank is 574.


Evoke Pharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 14.42 $ 12.79 $ 11.59 $ 10.25 $ 8.62
Y / Y Revenue Growth (TTM) 67.4 % 70.02 % 89.89 % 97.84 % 100.35 %
Year on Year Revenue Growth Overall Ranking # 93 # 76 # 68 # 50 # 116
Seqeuential Revenue Change (TTM) 12.74 % 10.36 % 13.12 % 18.94 % 14.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 922 # 414 # 550 # 400 # 575


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2025 period, Evoke Pharma Inc 's cumulative twelve months Revenue were $ 14 millions, company would post below average annual Revenue growth of 14.5% year on year, if the fiscal year would end at Sep 30 2025.
A slow-down in the Evoke Pharma Inc 's Revenue growth from the 3.75% growth in Jun 30 2025.

Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 76 to 93.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 31
Overall # 93

Revenue TTM Y/Y Growth Statistics
High Average Low
110.79 %
 83.94 %
49.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 71
Sector # 181
S&P 500 # 922
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2025 period, Evoke Pharma Inc 's cumulative twelve months Revenue were $ 14 millions, company would post below average annual Revenue growth of 49.06% year on year, if the fiscal year would end at Sep 30 2025.
A slow-down in the Evoke Pharma Inc 's Revenue growth from the 3.75% growth in Jun 30 2025.

Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 76 to 93.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 31
Overall # 93

Revenue TTM Y/Y Growth Statistics
High Average Low
110.79 %
83.94 %
49.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 71
Sector # 181
S&P 500 # 922




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EVOK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Neuronetics Inc 106.14%$ 106.144 millions
Abvc Biopharma Inc 104.47%$ 104.469 millions
Adaptive Biotechnologies Corporation102.38%$ 102.375 millions
Elite Pharmaceuticals Inc 98.23%$ 98.231 millions
Carlsmed Inc 96.16%$ 96.161 millions
Tg Therapeutics Inc 92.79%$ 92.788 millions
Bolt Biotherapeutics Inc 90.10%$ 90.096 millions
Delcath Systems Inc 88.82%$ 88.816 millions
Profound Medical Corp 86.76%$ 86.758 millions
Kaya Holdings Inc 80.27%$ 80.267 millions
Fennec Pharmaceuticals Inc 78.69%$ 78.692 millions
Vivos Therapeutics Inc 78.07%$ 78.074 millions
Insmed Inc77.99%$ 77.994 millions
Premier Air Charter Holdings Inc 75.89%$ 75.893 millions
Zymeworks Inc 72.59%$ 72.588 millions
Hologic Inc71.51%$ 71.508 millions
Legend Biotech Corporation69.99%$ 69.988 millions
Assertio Holdings inc 69.36%$ 69.357 millions
Esperion Therapeutics Inc 69.10%$ 69.099 millions
Bespoke Extracts Inc68.63%$ 68.630 millions
Xenetic Biosciences Inc 67.19%$ 67.191 millions
Geron Corporation67.05%$ 67.051 millions
Axsome Therapeutics Inc 63.22%$ 63.219 millions
Beta Bionics Inc 62.34%$ 62.341 millions
Uniqure N v 61.83%$ 61.828 millions
Evoke Pharma Inc 61.40%$ 61.405 millions
Kiniksa Pharmaceuticals International Plc61.17%$ 61.170 millions
Precision Optics Corporation Inc 59.18%$ 59.179 millions
Assembly Biosciences Inc 57.62%$ 57.619 millions
Akebia Therapeutics Inc 57.01%$ 57.011 millions


About Evoke Pharma Inc Revenue Growth Rates (EVOK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Evoke Pharma Inc (CIK 1403708).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-25-278802
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Evoke Pharma Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.